Corrigendum to “The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity” [Pharmacol. Res. 231 (2026) 108365]
Pharmacological Research · 2026-11 · 109738
DOI: 10.1016/j.phrs.2026.109738 ↗Kurz gefasst
Korrektur in der Zeitschrift Pharmacological Research, 2026-11. Verfasst von Robert Roskoski. Beteiligte Einrichtung: Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States. Electronic address: rrj@brimr.org. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States. Electronic address: rrj@brimr.org.
Zitieren
APA
Roskoski, R. (2026). Corrigendum to “The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity” [Pharmacol. Res. 231 (2026) 108365]. Pharmacological Research, 109738. https://doi.org/10.1016/j.phrs.2026.109738
Vancouver
Roskoski R. Corrigendum to “The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity” [Pharmacol. Res. 231 (2026) 108365]. Pharmacological Research. 2026:109738. doi:10.1016/j.phrs.2026.109738
BibTeX
@article{Roskoski2026,
author = {Roskoski, Robert},
title = {Corrigendum to “The role of GLP-1 and GIP receptor agonists in the treatment of diabetes and obesity” [Pharmacol. Res. 231 (2026) 108365]},
journal = {Pharmacological Research},
year = {2026},
pages = {109738},
doi = {10.1016/j.phrs.2026.109738}
}
EUVIMED